Skip to content
Oncology Research Hub

Cleveland, Ohio

Cancer clinical trials in Cleveland, OH

205 cancer studies are recruiting participants at sites in Cleveland as of November 16, 2026, according to ClinicalTrials.gov. Oncology Research Hub can help you understand your options and connect with a study team.

Call (888) 343-1186
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Cleveland at a glance

  • 205 studies are recruiting at a site in Cleveland.
  • By phase: Phase 1 (37), Phase 1/2 (41), Phase 2 (36), Phase 2/3 (9), Phase 3 (53), Phase 4 (1), No phase (20), Observational (8). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (131), university, hospital or other (54), government (20).
  • By research area: Lung Cancer (63), Lymphoma (47), Breast Cancer (43), Prostate Cancer (31), Pancreatic Cancer (11), Melanoma (10).
  • Most recent update to one of these records: November 16, 2026.

Breast cancer studies recruiting in Cleveland

Basic details from each study's public record (the 30 most recently updated of 205). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    LeonaBio
    Study site
    University Hospitals Seidman Cancer Center
    Registry record
    NCT05696626 · updated
  2. S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Case Western Reserve University · Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation
    Registry record
    NCT03418961 · updated
  3. Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

    • Phase 2
    • All ages
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT05564377 · updated
  4. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    MetroHealth Medical Center
    Registry record
    NCT06058377 · updated
  5. A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

    • Phase 1
    • Ages 18 to 55
    • Female participants
    Sponsor
    TerSera Therapeutics LLC
    Study site
    Cleveland Clinic Foundation
    Registry record
    NCT07310420 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Lung cancer studies recruiting in Cleveland

  1. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT06287775 · updated
  2. A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Novelty Nobility, Inc.
    Study site
    Case Comprehensive Cancer Center
    Registry record
    NCT06805825 · updated
  3. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Cleveland Clinic Taussig Cancer Institute Case Comprehensive Cancer Center
    Registry record
    NCT07111520 · updated
  4. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation · MetroHealth Medical Center
    Registry record
    NCT04267848 · updated
  5. Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT04665739 · updated
  6. Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Cleveland Clinic
    Registry record
    NCT04886804 · updated
  7. Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

    • Phase 3
    • Ages 70 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Case Western Reserve University · MetroHealth Medical Center
    Registry record
    NCT06096844 · updated
  8. This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT06758401 · updated
  9. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT07100080 · updated
  10. A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Cleveland Clinic - Ohio ( Site 0016)
    Registry record
    NCT07221474 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Prostate cancer studies recruiting in Cleveland

  1. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospitals Cleveland Medical Center ( Site 0043)
    Registry record
    NCT06136624 · updated
  2. Sacral Neuromodulation for Male Overactive Bladder (MOAB)

    • No phase
    • Ages 18 and older
    • Male participants
    Sponsor
    Axonics, Inc.
    Study site
    University Hospitals Cleveland
    Registry record
    NCT06511141 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Melanoma studies recruiting in Cleveland

  1. Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma

    • Phase 3
    • Ages 75 and older
    • All sexes
    Sponsor
    ECOG-ACRIN Cancer Research Group
    Study site
    Case Western Reserve University
    Registry record
    NCT07068074 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Cleveland, OH on ClinicalTrials.gov.

Lymphoma studies recruiting in Cleveland

  1. A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    The Cleveland Clinic Foundation
    Registry record
    NCT07221500 · updated
  2. A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study sites
    Cleveland Clinic Main ( Site 0101) · Fairview Hospital-Moll Cancer Center ( Site 0198) · University Hospitals of Cleveland ( Site 0155)
    Registry record
    NCT06890884 · updated
  3. A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospitals of Cleveland ( Site 0113)
    Registry record
    NCT07519772 · updated
  4. A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Hospitals of Cleveland ( Site 1321)
    Registry record
    NCT07634471 · updated
  5. Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cleveland Clinic Cancer Center/Fairview Hospital · Cleveland Clinic Foundation
    Registry record
    NCT04269902 · updated
  6. A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

    • Phase 2
    • Ages 1 to 30
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Rainbow Babies and Childrens Hospital
    Registry record
    NCT04546399 · updated
  7. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study sites
    Cleveland Clinic Foundation · Rainbow Babies and Childrens Hospital
    Registry record
    NCT05675410 · updated
  8. A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    University Hospitals Cleveland Medical Center
    Registry record
    NCT06091254 · updated
  9. Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT06337318 · updated
  10. A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    University Hospitals
    Registry record
    NCT06846671 · updated
  11. Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Case Western Reserve University
    Registry record
    NCT07003295 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Cleveland, OH on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Cleveland

  1. A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Incyte Corporation
    Study sites
    Investigative Site US020 · Investigative Site US050
    Registry record
    NCT07522073 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Cleveland, OH on ClinicalTrials.gov.

Ask about studies near Cleveland

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Ohio

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Oncology Research Hub does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 343-1186

or send a short form

How should we reach you?

Call